Patent 7829674 was granted and assigned to Lpath on November, 2010 by the United States Patent and Trademark Office.
The present invention relates to anti-S1P agents, for example, humanized monoclonal antibodies, and their uses for detection of S1P or for treatment of diseases and conditions associated with S1P.